Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Titel:
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Auteur:
Khattak, Muhammad A. Luke, Jason J. Long, Georgina V. Ascierto, Paolo A. Rutkowski, Piotr Schadendorf, Dirk Robert, Caroline Grob, Jean-Jacques de la Cruz Merino, Luis Del Vecchio, Michele Spagnolo, Francesco Mackiewicz, Jacek Chiarion-Sileni, Vanna Carlino, Matteo S. Mohr, Peter De Galitiis, Federica Ross, Merrick I. Eroglu, Zeynep Chen, Ke Jiang, Ruixuan Fukunaga-Kalabis, Mizuho Krepler, Clemens Eggermont, Alexander M.M. Kirkwood, John M.
Verschenen in:
European journal of cancer
Paginering:
Jaargang 176 () nr. C pagina's 207-217
Jaar:
2022
Inhoud:
Uitgever:
The Author(s), Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.,